To interrupt this process, CDK inhibitors have been developed for cancer treatment with the success of FDA-approved CDK4/6 inhibitors to treat certain types of hormone receptor-positive, HER2-negative breast cancers [30]. This evidence concerns the gene ERBB2 and breast cancer.